ABBV insider ownership: who sold, why, and what they still hold

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Nicholas Donoghoe EVP, Chief Bus/Strat Officer	32,710	$250.00	31%	74K	Aug 14, 2026	Aug 18, 2026

What stands out

Two officers sold $9.4M with no disclosed plan: Nicholas Donoghoe ($8.2M) and David Purdue ($1.2M). The filings don't state a reason.Nicholas Donoghoe: largest such sale, Aug 14, 2026 · David Purdue: largest such sale, Mar 4, 2026

Selling rose in the last 90 days but the year remains well below the 5-year average: officers and directors sold 33K shares, against an average of 15K per 90 days earlier in the period. Most of it was Nicholas Donoghoe (33K shares in the last 90 days); 0% of these sales were under disclosed plans.Nicholas Donoghoe: largest recent sale, Aug 14, 2026

Tax withholding outweighed market sales: the company withheld $32.0M of officers' and directors' shares for taxes, against $18.9M sold on the open market. The largest was Robert Michael ($8.5M withheld).Largest withholding, Feb 27, 2026

Percentages cover 18 of 22 officers and directors. 4 are left out

Left out: Nicholas Donoghoe and Perry Siatis (most of their shares vested during the period, so a percentage would mislead); Roopal Thakkar and David Purdue (holdings couldn't be fully reconciled).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is the insider's vested stake at the start of the period (Oct 8, 2025). The gold part is what they sold.

SoldRest of starting stakeAdded during the period

Perry Siatis

EVP, GC and Secretary

No bar: most of their shares vested during the period, so a percentage would mislead.

$9.5MDisclosed plan

Nicholas Donoghoe

EVP, Chief Bus/Strat Officer

No bar: most of their shares vested during the period, so a percentage would mislead.

$8.2MNo plan disclosed

David Purdue

SVP, Controller

No bar: holdings couldn't be fully reconciled.

$1.2MNo plan disclosed

Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosed

Outside holders, reported separately

AbbVie Inc. reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the AbbVie Inc. CEO selling stock?

No. Robert Michael reported no open-market sales in the past 12 months.

Why are AbbVie Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 50% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 50% had no disclosed plan. A trading plan schedules sales in advance.

Are any AbbVie Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold3 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Perry Siatis EVP, GC and Secretary	$9.5M 41K shares	i No percentage: most of their shares vested during the period, so a percentage would mislead.	Disclosed plan
Nicholas Donoghoe EVP, Chief Bus/Strat Officer	$8.2M 33K shares	i No percentage: most of their shares vested during the period, so a percentage would mislead.	No plan disclosed
David Purdue SVP, Controller	$1.2M 5.2K shares	i No percentage: holdings couldn't be fully reconciled.	No plan disclosed

Outside holder, reported separately: AbbVie Inc. (a 10% owner, not part of management). No open-market sales reported in the period. Holds 5.9K shares. Latest filing

The full ownership picture20 of 22 insiders fully reconciled · 22 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 8, 2025

Sold

Held Oct 8, 2026

Still held

Azita Saleki-Gerhardt

Minor difference of 59 shares. Difference is under 0.5% of holdings.

EVP, Chief Operations Officer

188K

208K

no sales

Vesting, gifts, unvested awards and holding lines for Azita Saleki-Gerhardt

0shares vested or exercised

0gifted (net of own trusts)

−16Kwithheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
spouse in trust	Common Stock, $0.01 par value	3,873	3,873
Direct	Common stock, $0.01 par value	177,292	197,794
Spouse	Common stock, $0.01 par value	3,873	3,873
Profit sharing trust	Common stock, $0.01 par value	2,647	2,706

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,313	$0.00	Feb 14, 2034	$7.3M
25,000	$192.86	Feb 12, 2035	$1.4M
20,312	$230.04	Feb 17, 2036	$405K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Reconciliation: minor difference of 59 shares. Difference is under 0.5% of holdings.

Thomas Freyman

Includes unvested RSUs, amount not disclosed. New Form 3 filed 2020-05-12; earlier filings set aside.

Director

135K

136K

no sales

Vesting, gifts, unvested awards and holding lines for Thomas Freyman

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
New Form 3 filed 2020-05-12; earlier filings set aside.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	126,751	127,869
spouse in trust	Common Stock, $0.01 par value	4,000	4,000
spouse in trust for son	Common Stock, $0.01 par value	3,882	3,882

Robert Michael

Chairman of the Board and CEO, Director

133K

179K

no sales

Vesting, gifts, unvested awards and holding lines for Robert Michael

0shares vested or exercised

0gifted (net of own trusts)

−37Kwithheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock, $0.01 par value	132,821	178,737

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
59,888	$0.00	Feb 14, 2034	$15.0M
83,333	$192.86	Feb 12, 2035	$4.8M
81,251	$230.04	Feb 17, 2036	$1.6M

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Edward Rapp

Minor difference of 11,239 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends. Includes unvested RSUs, amount not disclosed. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Director

73K

86K

no sales

Vesting, gifts, unvested awards and holding lines for Edward Rapp

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
spouse in trust	Common Stock, $0.01 par value	10,388	10,388
Direct includes unvested RSUs, amount not disclosed	Common stock, $0.01 par value	34,458	45,964
Direct	Stock Equivalent Units	28,152	29,568

Reconciliation: minor difference of 11,239 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Nicholas Donoghoe

New Form 3 filed 2023-07-10; earlier filings set aside.

EVP, Chief Bus/Strat Officer

58K

−33K

74K

not meaningful

Vesting, gifts, unvested awards and holding lines for Nicholas Donoghoe

+33Kshares vested or exercised

0gifted (net of own trusts)

−13Kwithheld by the company for taxes

none reportedunvested awards, start → end

New Form 3 filed 2023-07-10; earlier filings set aside.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock, $0.01 par value	58,247	74,430

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
21,433	$0.00	Feb 14, 2034	$5.4M
23,437	$192.86	Feb 12, 2035	$1.3M
20,312	$230.04	Feb 17, 2036	$405K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Jeffrey Stewart

Includes unvested RSUs, amount not disclosed.

EVP, Chief Commercial Officer

55K

85K

no sales

Vesting, gifts, unvested awards and holding lines for Jeffrey Stewart

0shares vested or exercised

0gifted (net of own trusts)

−24Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	53,234	83,171
spouse in trust	Common Stock, $0.01 par value	1,338	1,338

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
39,085	$0.00	Feb 14, 2034	$9.8M
33,854	$192.86	Feb 12, 2035	$1.9M
26,812	$230.04	Feb 17, 2036	$535K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Glenn Tilton

Includes unvested RSUs, amount not disclosed. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Director

52K

no sales

Vesting, gifts, unvested awards and holding lines for Glenn Tilton

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	51,564	51,564
Spouse	Common Stock, $0.01 par value	350	350

Additional holdings last reported Apr 28, 2023, not confirmed since: 34,700 shares. Not included in any total or percentage on this page.

Direct, Stock Equivalent Units: 34,700 shares, last reported Apr 28, 2023

Robert Alpern

Minor difference of 149 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed.

Director

46K

no sales

Vesting, gifts, unvested awards and holding lines for Robert Alpern

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	35,646	35,646
Direct	Stock Equivalent Units	10,151	10,369

Reconciliation: minor difference of 149 shares. Difference is under 0.5% of holdings.

Roopal Thakkar

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +2,998 shares on Feb 27, 2026 (Profit sharing trust). See the filing Sales and other transactions for Roopal Thakkar are complete.

EVP, R&D and CSO

n/a

Vesting, gifts, unvested awards and holding lines for Roopal Thakkar

0shares vested or exercised

0gifted (net of own trusts)

−8Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +2,998 shares on Feb 27, 2026 (Profit sharing trust). The balances below are as reported, not verified totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	42,276	52,376
Profit sharing trust	Common Stock, $0.01 par value	0	2,998

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
18,003	$93.50	Feb 19, 2030	$2.8M
7,763	$105.92	Feb 17, 2031	$1.1M
7,005	$144.54	Feb 16, 2032	$739K
8,102	$149.62	Feb 15, 2033	$813K
13,868	$175.28	Feb 14, 2034	$1.0M
25,000	$192.86	Feb 12, 2035	$1.4M
21,937	$230.04	Feb 17, 2036	$438K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Roxanne Austin

Includes unvested RSUs, amount not disclosed.

Director

38K

40K

no sales

Vesting, gifts, unvested awards and holding lines for Roxanne Austin

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	38,458	39,576

Frederick Waddell

Includes unvested RSUs, amount not disclosed.

Director

29K

30K

no sales

Vesting, gifts, unvested awards and holding lines for Frederick Waddell

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common stock, $0.01 par value	28,958	30,076

William Burnside

Includes unvested RSUs, amount not disclosed.

Director

27K

28K

no sales

Vesting, gifts, unvested awards and holding lines for William Burnside

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	26,958	28,076

Brett Hart

Includes unvested RSUs, amount not disclosed.

Director

19K

21K

no sales

Vesting, gifts, unvested awards and holding lines for Brett Hart

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	19,472	20,590

Melody Meyer

Includes unvested RSUs, amount not disclosed.

Director

16K

18K

no sales

Vesting, gifts, unvested awards and holding lines for Melody Meyer

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	16,498	17,616

Rebecca Roberts

Includes unvested RSUs, amount not disclosed.

Director

14K

15K

no sales

Vesting, gifts, unvested awards and holding lines for Rebecca Roberts

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	13,728	14,846

Scott Reents

EVP, Chief Financial Officer

12K

39K

no sales

Vesting, gifts, unvested awards and holding lines for Scott Reents

0shares vested or exercised

0gifted (net of own trusts)

−22Kwithheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock, $0.01 par value	11,577	38,777

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
31,520	$0.00	Feb 14, 2034	$7.9M
17,380	$61.36	Feb 15, 2027	$3.3M
27,343	$192.86	Feb 12, 2035	$1.6M
21,937	$230.04	Feb 17, 2036	$438K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Demetris Crum

Includes unvested RSUs, amount not disclosed. Unvested RSUs stated in footnotes are excluded from owned shares.

EVP, Chief HR Officer

5.9K

7.9K

no sales

Vesting, gifts, unvested awards and holding lines for Demetris Crum

0shares vested or exercised

0gifted (net of own trusts)

−1.6Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unvested RSUs stated in footnotes are excluded from owned shares.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	5,935	7,914

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,043	$175.28	Feb 14, 2034	$377K
4,687	$192.86	Feb 12, 2035	$268K
13,406	$230.04	Feb 17, 2036	$268K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

David Purdue

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: -2,111 shares on Mar 4, 2026 (Direct). See the filing Sales and other transactions for David Purdue are complete.

SVP, Controller

n/a

−5.2K

n/a

Vesting, gifts, unvested awards and holding lines for David Purdue

0shares vested or exercised

0gifted (net of own trusts)

−2.1Kwithheld by the company for taxes

none reportedunvested awards, start → end

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: -2,111 shares on Mar 4, 2026 (Direct). The balances below are as reported, not verified totals.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock, $0.01 par value	4,505	543
Profit sharing trust	Common Stock, $0.01 par value	527	543

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,376	$149.62	Feb 15, 2033	$339K
5,358	$175.28	Feb 14, 2034	$400K
5,208	$192.86	Feb 12, 2035	$298K
4,875	$230.04	Feb 17, 2036	$97K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Perry Siatis

EVP, GC and Secretary

4.6K

−41K

4.6K

not meaningful

Vesting, gifts, unvested awards and holding lines for Perry Siatis

+22Kshares vested or exercised

0gifted (net of own trusts)

−15Kwithheld by the company for taxes

none reportedunvested awards, start → end

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct	Common Stock, $0.01 par value	4,619	4,619

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,837	$144.54	Feb 16, 2032	$616K
23,324	$0.00	Feb 14, 2034	$5.8M
2,919	$144.54	Feb 16, 2032	$308K
14,583	$192.86	Feb 12, 2035	$833K
7,774	$175.28	Feb 14, 2034	$581K
19,500	$230.04	Feb 17, 2036	$389K

Estimate: options held × ($250.00 − strike price), using the most recent insider trade price on Form 4 (Aug 14, 2026), not a market close.

Thomas Falk

Includes unvested RSUs, amount not disclosed. Held through limited partnership; the director disclaims ownership beyond their own interest.

Director

4.2K

5.3K

no sales

Vesting, gifts, unvested awards and holding lines for Thomas Falk

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Held through limited partnership; the director disclaims ownership beyond their own interest.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	1,203	2,321
limited partnership	Common Stock, $0.01 par value	3,000	3,000

Susan Quaggin

Minor difference of 24 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends. Includes unvested RSUs, amount not disclosed. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Director

3.2K

4.6K

no sales

Vesting, gifts, unvested awards and holding lines for Susan Quaggin

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	2,525	3,643
Direct	Stock Equivalent Units	634	918

Reconciliation: minor difference of 24 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Jennifer Davis

Includes unvested RSUs, amount not disclosed.

Director

2.5K

3.6K

no sales

Vesting, gifts, unvested awards and holding lines for Jennifer Davis

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 8, 2025	Oct 8, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock, $0.01 par value	2,525	3,643

20 of 22 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (16 exactly, 4 with a minor or footnoted difference). For 2 we show sales but not holdings; the ! icon on their rows explains why. Percentages cover 18 of 22 officers and directors. Left out: Nicholas Donoghoe and Perry Siatis (most of their shares vested during the period, so a percentage would mislead); Roopal Thakkar and David Purdue (holdings couldn't be fully reconciled). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$18.9M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $18.9M across 78,989 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $9.5M · 50%

50%

The lighter segment is sales with no plan disclosed in the filing ($9.4M), including tax-related sales outside a plan.

No plan disclosed · $9.4M

Sales with no 10b5-1 plan and no tax reference in the filing. $8.2M of it is Nicholas Donoghoe. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Nicholas Donoghoe, Aug 14, 2026

Taxes

137,745 shares ($32.0M) were withheld by the company for taxes, which isn't a market sale.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Perry Siatis EVP, GC and Secretary	41K	$9.5M	100%	50%	Feb 25, 2026 to Mar 2, 2026
Nicholas Donoghoe EVP, Chief Bus/Strat Officer	33K	$8.2M	0%	43%	Aug 14, 2026 to Aug 14, 2026
David Purdue SVP, Controller	5.2K	$1.2M	0%	6%	Mar 4, 2026 to Mar 4, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$5.1M	$5.1M	$0	$0
Mar 2026	$5.6M	$4.4M	$0	$1.2M
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$8.2M	$0	$0	$8.2M
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about one-tenth of the 5-year average. 3 insiders sold; the average is 9 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 8, 2026 Latest 12 months	79K	3	$18.9M
Oct 8, 2025 1 year earlier	336K	8	$69.1M
Oct 8, 2024 2 years earlier	811K	9	$144M
Oct 9, 2023 3 years earlier	413K	9	$63.4M
Oct 9, 2022 4 years earlier	1.35M	11	$191M
Oct 9, 2021 5 years earlier	919K	9	$94.6M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty2 insiders whose holdings couldn't be fully reconciled

Roopal Thakkar: holdings couldn't be fully reconciled (difference of 2,998 shares). Balance changed without a matching transaction, and the footnote does not state the amount: +2,998 shares on Feb 27, 2026 (Profit sharing trust). Filing, Feb 27, 2026

Footnote: "Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature. This was inadvertently omitted from the Form 3 filed on December 22, 2023."

David Purdue: holdings couldn't be fully reconciled (difference of -2,679 shares). Balance changed without a matching transaction, and the footnote does not state the amount: -2,111 shares on Mar 4, 2026 (Direct). Filing, Mar 4, 2026

Footnote: "Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature."

Azita Saleki-Gerhardt: minor difference of 59 shares. Difference is under 0.5% of holdings.

Edward Rapp: minor difference of 11,239 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Robert Alpern: minor difference of 149 shares. Difference is under 0.5% of holdings.

Susan Quaggin: minor difference of 24 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Inferred rename: "son" is treated as the same holder as "spouse in trust for son", because the old name was never reported again and the new one opened with the same balance (1,941 shares). Old name, new name

Inferred rename: "child" is treated as the same holder as "step-daughter", because the old name was never reported again and the new one opened with the same balance (450 shares). Old name, new name

Inferred typo: the share class "Common Stock, $0.01 par share" is treated as the same class as "Common Stock, $0.01 par shar" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Henry Gosebruch, 53,106 shares): old title, new title

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology872 filings from SEC EDGAR, and how we read them

All 872 Forms 3, 4 and 5 filed for AbbVie Inc. (SEC CIK 1551152) from Dec 7, 2012 to Oct 2, 2026, retrieved from SEC EDGAR on Oct 8, 2026. Prices are the ones reported in each filing, often weighted averages. 3 filings were left out because AbbVie Inc. filed them as an owner of another company's stock.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (18)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Richard Gonzalez	Apr 2, 2025	415,894 shares, last reported balance as of Mar 31, 2025
Timothy Richmond	Mar 4, 2025	6,130 shares, last reported balance as of Mar 3, 2025
Kevin Buckbee	Mar 4, 2025	7,797 shares, last reported balance as of Feb 28, 2025
Thomas Hudson	Mar 1, 2024	107,267 shares, last reported balance as of Feb 28, 2024
Carrie Strom	May 12, 2023	28,024 shares, last reported balance as of May 11, 2023
Elaine Sorg	Apr 27, 2023	35,330 shares, last reported balance as of Apr 25, 2023
Brian Durkin	Mar 2, 2023	33,402 shares, last reported balance as of Feb 28, 2023
Michael Severino	May 25, 2022	152,103 shares, last reported balance as of May 23, 2022
Henry Gosebruch	May 20, 2022	253,768 shares, last reported balance as of May 16, 2022
Edward Liddy	Apr 4, 2022	55,157 shares, last reported balance as of Mar 31, 2022
Laura Schumacher	Mar 1, 2022	248,002 shares, last reported balance as of Feb 25, 2022
Carlos Alban	Nov 18, 2020	155,341 shares, last reported balance as of Nov 16, 2020
William Chase	Jun 28, 2019	170,053 shares, last reported balance as of Jun 26, 2019
Thomas Hurwich	Mar 2, 2017	63,050 shares, last reported balance as of Feb 28, 2017
Roy Roberts	May 12, 2015	27,486 shares, last reported balance as of May 8, 2015
John Leonard	Mar 19, 2013	113,793 shares, last reported balance as of Mar 15, 2013
Laboratories Abbott	Dec 14, 2012	No balance on record
Greg Linder	Dec 7, 2012	No balance on record

AbbVie Inc. insiders sold $18.9M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Outside holders, reported separately

Common questions

Is the AbbVie Inc. CEO selling stock?

Why are AbbVie Inc. insiders selling?

Are any AbbVie Inc. insiders buying?

The evidence

No plan disclosed · $9.4M

Taxes

Sales by month